Abstract
The effects of neriifolin, a cardiac glycoside from Cerbera manghas L. on various end-points of oncologic relevance (cell growth, cell cycle regulation, and apoptosis in HepG2 cells) were investigated. Neriifolin reduced viability of HepG2 cells, induced S and G2/M phase arrests of the cell cycle, and stimulated apoptosis of HepG2 cells. Stimulation of HepG2 cells with neriifolin induced activation of caspase-3, -8, and -9, and up-regulated expression of Fas and FasL proteins. Based on these results, neriifolin could be considered a candidate for the treatment of hepatocellular carcinoma.
Copyright © 2011 Elsevier B.V. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Phytogenic / isolation & purification
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Apocynaceae / chemistry*
-
Apoptosis / drug effects*
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / metabolism
-
Cardenolides / isolation & purification
-
Cardenolides / pharmacology
-
Cardenolides / therapeutic use*
-
Caspases / metabolism
-
Cell Cycle / drug effects*
-
Fas Ligand Protein / metabolism
-
Fas-Associated Death Domain Protein / metabolism
-
Hep G2 Cells
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / metabolism
-
Phytotherapy*
-
Plant Extracts / chemistry
-
Plant Extracts / pharmacology
-
Plant Extracts / therapeutic use
-
Seeds
-
Up-Regulation
Substances
-
Antineoplastic Agents, Phytogenic
-
Cardenolides
-
Fas Ligand Protein
-
Fas-Associated Death Domain Protein
-
Plant Extracts
-
neriifolin
-
Caspases